Partners ||| S:0 E:8 ||| NNP
'  ||| S:8 E:10 ||| POS
representations  ||| S:10 E:26 ||| NN
of  ||| S:26 E:29 ||| IN
diabetes  ||| S:29 E:38 ||| NN
as  ||| S:38 E:41 ||| IN
mediators  ||| S:41 E:51 ||| NNS
between  ||| S:51 E:59 ||| IN
patients ||| S:59 E:67 ||| NNS
'  ||| S:67 E:69 ||| POS
representations  ||| S:69 E:85 ||| NNS
and  ||| S:85 E:89 ||| CC
adherence  ||| S:89 E:99 ||| JJ
to  ||| S:99 E:102 ||| TO
self-care  ||| S:102 E:112 ||| JJ
behaviors ||| S:112 E:121 ||| NN
,  ||| S:121 E:123 ||| ,
in  ||| S:123 E:126 ||| IN
type  ||| S:126 E:131 ||| NN
2  ||| S:131 E:133 ||| CD
diabetes  ||| S:133 E:142 ||| NN
The  ||| S:142 E:146 ||| DT
purpose  ||| S:146 E:154 ||| NN
of  ||| S:154 E:157 ||| IN
this  ||| S:157 E:162 ||| DT
study  ||| S:162 E:168 ||| NN
was  ||| S:168 E:172 ||| VBD
to  ||| S:172 E:175 ||| TO
analyze  ||| S:175 E:183 ||| VB
partners ||| S:183 E:191 ||| NNS
' ||| S:191 E:192 ||| POS
 representations  ||| S:192 E:209 ||| NN
of  ||| S:209 E:212 ||| IN
diabetes  ||| S:212 E:221 ||| NN
as  ||| S:221 E:224 ||| IN
mediators  ||| S:224 E:234 ||| NNS
between  ||| S:234 E:242 ||| IN
patients ||| S:242 E:250 ||| NNS
'  ||| S:250 E:252 ||| POS
illness  ||| S:252 E:260 ||| NN
representations  ||| S:260 E:276 ||| NNS
and  ||| S:276 E:280 ||| CC
adherence  ||| S:280 E:290 ||| JJ
to  ||| S:290 E:293 ||| TO
all  ||| S:293 E:297 ||| DT
self-care  ||| S:297 E:307 ||| JJ
behaviors ||| S:307 E:316 ||| NN
,  ||| S:316 E:318 ||| ,
in  ||| S:318 E:321 ||| IN
recently  ||| S:321 E:330 ||| RB
diagnosed  ||| S:330 E:340 ||| JJ
type  ||| S:340 E:345 ||| NN
2  ||| S:345 E:347 ||| CD
diabetes  ||| S:347 E:356 ||| NN
( ||| S:356 E:357 ||| -LRB-
T2DM ||| S:357 E:361 ||| NNP
)  ||| S:361 E:363 ||| -RRB-
patients ||| S:363 E:371 ||| NNS
.  ||| S:371 E:373 ||| .
The  ||| S:373 E:377 ||| DT
sample  ||| S:377 E:384 ||| NN
included  ||| S:384 E:393 ||| VBD
340  ||| S:393 E:397 ||| CD
patients and  ||| S:397 E:410 ||| CD
their  ||| S:410 E:416 ||| PRP$
respective  ||| S:416 E:427 ||| JJ
partners ||| S:427 E:435 ||| NNS
.  ||| S:435 E:437 ||| .
The  ||| S:437 E:441 ||| DT
instruments  ||| S:441 E:453 ||| NNS
used  ||| S:453 E:458 ||| VBN
were ||| S:458 E:462 ||| VBD
:  ||| S:462 E:464 ||| :
Revised  ||| S:464 E:472 ||| NNP
Summary  ||| S:472 E:480 ||| NNP
of  ||| S:480 E:483 ||| IN
Diabetes  ||| S:483 E:492 ||| NNP
Self-Care  ||| S:492 E:502 ||| NNP
Activities  ||| S:502 E:513 ||| NNPS
( ||| S:513 E:514 ||| -LRB-
RSDSCA ||| S:514 E:520 ||| NNP
) ||| S:520 E:521 ||| -RRB-
;  ||| S:521 E:523 ||| :
Medication  ||| S:523 E:534 ||| NNP
Adherence  ||| S:534 E:544 ||| NNP
Report  ||| S:544 E:551 ||| NNP
Scale  ||| S:551 E:557 ||| NNP
( ||| S:557 E:558 ||| -LRB-
MARS ||| S:558 E:562 ||| NNP
) ||| S:562 E:563 ||| -RRB-
;  ||| S:563 E:565 ||| :
and  ||| S:565 E:569 ||| CC
the  ||| S:569 E:573 ||| DT
Brief  ||| S:573 E:579 ||| NNP
Illness  ||| S:579 E:587 ||| NNP
Perception  ||| S:587 E:598 ||| NNP
Questionnaire  ||| S:598 E:612 ||| NNP
  ||| S:612 E:613 ||| NNP
( ||| S:613 E:614 ||| -LRB-
Brief-IPQ ||| S:614 E:623 ||| NNP
) ||| S:623 E:624 ||| -RRB-
.  ||| S:624 E:626 ||| .
A  ||| S:626 E:628 ||| DT
mediational  ||| S:628 E:640 ||| JJ
effect  ||| S:640 E:647 ||| NN
of  ||| S:647 E:650 ||| IN
partners ||| S:650 E:658 ||| NNS
'  ||| S:658 E:660 ||| POS
representation  ||| S:660 E:675 ||| NN
of  ||| S:675 E:678 ||| IN
diabetes  ||| S:678 E:687 ||| JJ
consequences  ||| S:687 E:700 ||| NNS
was  ||| S:700 E:704 ||| VBD
found  ||| S:704 E:710 ||| VBN
between  ||| S:710 E:718 ||| IN
the  ||| S:718 E:722 ||| DT
same patients ||| S:722 E:735 ||| NNP
'  ||| S:735 E:737 ||| POS
representations  ||| S:737 E:753 ||| JJ
and   ||| S:753 E:758 ||| CD
exercise ||| S:758 E:766 ||| NN
,  ||| S:766 E:768 ||| ,
foot  ||| S:768 E:773 ||| NN
care ||| S:773 E:777 ||| NN
,  ||| S:777 E:779 ||| ,
and  ||| S:779 E:783 ||| CC
self-monitoring  ||| S:783 E:799 ||| JJ
of  ||| S:799 E:802 ||| IN
blood  ||| S:802 E:808 ||| NN
glucose ||| S:808 E:815 ||| NN
.  ||| S:815 E:817 ||| .
Partners ||| S:817 E:825 ||| NNP
' ||| S:825 E:826 ||| POS
 representations  ||| S:826 E:843 ||| NN
of  ||| S:843 E:846 ||| IN
personal  ||| S:846 E:855 ||| JJ
and  ||| S:855 E:859 ||| CC
treatment  ||| S:859 E:869 ||| NN
control ||| S:869 E:876 ||| NN
,  ||| S:876 E:878 ||| ,
were  ||| S:878 E:883 ||| VBD
mediators  ||| S:883 E:893 ||| VBN
between  ||| S:893 E:901 ||| IN
the  ||| S:901 E:905 ||| DT
same  ||| S:905 E:910 ||| JJ
partners ||| S:910 E:918 ||| NNS
' ||| S:918 E:919 ||| POS
 representations  ||| S:919 E:936 ||| NNP
and  ||| S:936 E:940 ||| CC
self-monitoring  ||| S:940 E:956 ||| JJ
of  ||| S:956 E:959 ||| IN
blood  ||| S:959 E:965 ||| NN
glucose ||| S:965 E:972 ||| NN
.  ||| S:972 E:974 ||| .
No  ||| S:974 E:977 ||| DT
partners ||| S:977 E:985 ||| NNS
'  ||| S:985 E:987 ||| POS
representations  ||| S:987 E:1003 ||| JJ
mediated  ||| S:1003 E:1012 ||| JJ
patients ||| S:1012 E:1020 ||| NNS
'  ||| S:1020 E:1022 ||| POS
representation  ||| S:1022 E:1037 ||| NN
and  ||| S:1037 E:1041 ||| CC
adherence  ||| S:1041 E:1051 ||| JJ
to  ||| S:1051 E:1054 ||| TO
medication  ||| S:1054 E:1065 ||| NN
or  ||| S:1065 E:1068 ||| CC
diet  ||| S:1068 E:1073 ||| NNP
.  ||| S:1073 E:1075 ||| .
This  ||| S:1075 E:1080 ||| DT
study  ||| S:1080 E:1086 ||| NN
emphasized  ||| S:1086 E:1097 ||| VBD
partners ||| S:1097 E:1105 ||| NNS
'  ||| S:1105 E:1107 ||| POS
representations  ||| S:1107 E:1123 ||| NN
on  ||| S:1123 E:1126 ||| IN
patient ||| S:1126 E:1133 ||| NN
's  ||| S:1133 E:1136 ||| POS
adherence  ||| S:1136 E:1146 ||| NN
to  ||| S:1146 E:1149 ||| TO
exercise ||| S:1149 E:1157 ||| VB
, ||| S:1157 E:1158 ||| ,
 foot  ||| S:1158 E:1164 ||| CD
care  ||| S:1164 E:1169 ||| NN
and  ||| S:1169 E:1173 ||| CC
monitoring of  ||| S:1173 E:1187 ||| CD
blood  ||| S:1187 E:1193 ||| NN
glucose ||| S:1193 E:1200 ||| NN
,  ||| S:1200 E:1202 ||| ,
in  ||| S:1202 E:1205 ||| IN
recent  ||| S:1205 E:1212 ||| JJ
diagnosed  ||| S:1212 E:1222 ||| NN
T2DM  ||| S:1222 E:1227 ||| CD
patients ||| S:1227 E:1235 ||| NNS
.  ||| S:1235 E:1237 ||| .
Interventions  ||| S:1237 E:1251 ||| NNS
to  ||| S:1251 E:1254 ||| TO
promote  ||| S:1254 E:1262 ||| VB
adherence  ||| S:1262 E:1272 ||| JJ
in T2DM  ||| S:1272 E:1280 ||| NN
should  ||| S:1280 E:1287 ||| MD
promote  ||| S:1287 E:1295 ||| VB
convergence  ||| S:1295 E:1307 ||| VBN
between  ||| S:1307 E:1315 ||| IN
patients  ||| S:1315 E:1324 ||| NNS
and  ||| S:1324 E:1328 ||| CC
partners ||| S:1328 E:1336 ||| NNS
'  ||| S:1336 E:1338 ||| POS
diabetes  ||| S:1338 E:1347 ||| NN
representations ||| S:1347 E:1362 ||| NNS
.  ||| S:1362 E:1364 ||| .
This  ||| S:1364 E:1369 ||| DT
study  ||| S:1369 E:1375 ||| NN
provides  ||| S:1375 E:1384 ||| VBZ
some  ||| S:1384 E:1389 ||| DT
evidence  ||| S:1389 E:1398 ||| NN
for  ||| S:1398 E:1402 ||| IN
the  ||| S:1402 E:1406 ||| DT
need  ||| S:1406 E:1411 ||| NN
to  ||| S:1411 E:1414 ||| TO
treat  ||| S:1414 E:1420 ||| VB
T2DM within  ||| S:1420 E:1432 ||| CD
the  ||| S:1432 E:1436 ||| DT
dyad  ||| S:1436 E:1441 ||| NN
to  ||| S:1441 E:1444 ||| TO
improve  ||| S:1444 E:1452 ||| VB
adherence ||| S:1452 E:1461 ||| NNS
,  ||| S:1461 E:1463 ||| ,
starting  ||| S:1463 E:1472 ||| VBG
after  ||| S:1472 E:1478 ||| IN
the  ||| S:1478 E:1482 ||| DT
diagnosis ||| S:1482 E:1491 ||| NN
.  ||| S:1491 E:1493 ||| .
